Consequently our intention was to analyse the distribution of angiogenic markers: sFlt1, PlGF, VEGF, VEGF-C and VEGF-D and disclose the differences of their expression in breast cancer patients of the SUCCESS study group in terms of CTC involvement, histo-pathological grading, lymph node metastasis, hormone receptor status, TNM classification and survived breast cancer patients vs. deceased tumour associated patients. This evidence concerns the gene VEGFD and breast carcinoma.